Key Highlights

  • Third-quarter 2026 Revenue was USD 9.1 million, against USD 9.7 million.
  • Net loss was USD 31.5 million, or USD 1.90 per share.
  • Research and development expenses were USD 23.5 million, against USD 39.9 million.
  • Cash, cash equivalents and marketable securities were USD 142.2 million.

Sutro Biopharma (NASDAQ:STRO) reported revenue of USD 9.1 million for the third quarter ended September 30, 2026, against an estimate of USD 14.1 million and USD 9.7 million in the third quarter of 2025. Net loss was USD 1.90 per share, against an estimate of a loss of USD 1.64 and a loss of USD 6.66 a year earlier. The South San Francisco company develops site-specific and novel-format antibody drug conjugates for oncology.

Quarterly Financial Results

Research and development expenses were USD 23.5 million, against USD 39.9 million, and general and administrative expenses were USD 7.5 million, against USD 8.7 million. Restructuring and related costs were USD 16 thousand, against USD 9.6 million. Total operating expenses were USD 31.1 million, against USD 58.2 million, and loss from operations was USD 22.0 million, against USD 48.5 million.

Interest income was USD 1.5 million, against USD 2.0 million. Non-cash interest expense related to the sale of future royalties was USD 10.2 million, against USD 9.7 million. Interest and other expense, net was USD 0.8 million, against USD 0.7 million. Net loss was USD 31.5 million, against USD 56.9 million, and weighted-average shares were 16,583,806, against 8,540,708. Comprehensive loss was USD 31.5 million.

The filing states that Sutro earned a USD 10.0 million contingent payment from Astellas in the third quarter of 2026 for dosing of the first subject in a Phase 1 clinical trial in the territory for its first program under the collaboration.

Nine-Month Results

For the nine months ended September 30, 2026, revenue was USD 33.5 million, against USD 90.8 million, with Astellas revenue of USD 33.2 million, against USD 33.9 million. The prior-year period included Ipsen agreement revenue of USD 56.4 million, and none was recorded in 2026. Research and Development expenses were USD 91.7 million, against USD 129.8 million, and general and administrative expenses were USD 23.0 million, against USD 32.4 million. Restructuring costs were USD 0.3 million, against USD 49.0 million.

Loss from operations was USD 81.5 million, against USD 120.3 million. Net loss was USD 108.5 million, or USD 7.03 per share, against USD 144.3 million, or USD 17.03 per share. The filing cites USD 29.5 million of non-cash interest expense on the deferred Royalty obligation, USD 5.7 million of stock-based compensation and USD 3.8 million of Depreciation and amortization in the nine-month net loss.

Liquidity and Financing

As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 142.2 million and an accumulated Deficit of USD 1,086.5 million. Net cash used in Operating Activities was USD 103.0 million for the nine months, against USD 150.8 million.

Financing activities provided USD 102.8 million, including USD 102.7 million of net proceeds from sales of common stock. In the February 2026 offering the company agreed to sell 7,868,383 shares at USD 13.98 per share, for gross proceeds of approximately USD 110.0 million before Underwriting discounts, commissions and expenses.

The Liability related to the sale of future Vaxcyte royalties was USD 219.5 million at the beginning of 2026, with USD 29.5 million of non-cash interest expense recorded in the nine-month period. Accruals related to the Vaxcyte Supply agreement were USD 7.1 million as of September 30, 2026, against USD 12.7 million at year-end 2025.

The company states that, under its current operating plan, it believes available cash, cash equivalents and marketable securities are sufficient to fund operations through at least the next 12 months.